CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer
NCT05685602
Recruiting
This phase I trial tests the safety, side effects, and best dose of emavusertib (CA-4948) in combination with gemcitabine and nab-paclitaxel in treating patients with pancreatic ductal adenocarcinoma that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (unresectable). CA-4948 is in a class of medications called kinase inhibitors. It works by blocking the action of abnormal proteins called interleukin-1 receptor-associ... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: City of Hope Comprehensive Cancer Center, Duarte, California +26 locations
Conditions: Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
Register for Updates
A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy
NCT05808764
Recruiting
This study will evaluate the pharmacokinetics (PK) and safety of risdiplam in participants with spinal muscular atrophy (SMA) under 20 days of age at first dose.
Gender:
ALL
Ages:
19 days and below
Trial Updated:
04/25/2025
Locations: Ann and Robert H. Lurie Children Hospital of Chicago, Chicago, Illinois +12 locations
Conditions: Muscular Atrophy, Spinal
Register for Updates
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers
NCT05891171
Recruiting
The primary purpose of this study is to assess the safety and tolerability of AB598 in participants with advanced malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Mayo Clinic Arizona, Phoenix, Arizona +19 locations
Conditions: Advanced Cancer, Advanced Malignancies, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer (GEJ), Head and Neck Squamous Cell Carcinoma (HNSCC), Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Renal Cell Carcinoma (RCC), Triple Negative Breast Cancer (TNBC)
Register for Updates
A Phase 1/Phase 2 Open-label Study to Evaluate the Safety, Tolerability, and Efficacy of a Single Intravenous Administration of SAR444836 in Adult Participants With Phenylketonuria
NCT05972629
Recruiting
This is a single group Phase 1/Phase 2, 1-arm, open-label study with SAR444836, an adeno-associated virus (AAV) vector-mediated gene transfer of human phenylalanine hydroxylase (PAH), for the treatment of adult participants with phenylketonuria (PKU) on a chronic, stable diet. The purpose of the study is to evaluate the safety and efficacy of SAR444836 in reducing phenylalanine (Phe) levels and in the elimination of a Phe restricted diet. Participants will receive a one-time intravenous (IV) ad... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/25/2025
Locations: University of California San Francisco - Parnassus Heights- Site Number : 8400007, San Francisco, California +9 locations
Conditions: Phenylketonuria
Register for Updates
A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma
NCT06084884
Recruiting
A Phase I/II study to evaluate AZD5851 in patients with GPC3+ advanced/recurrent hepatocellular carcinoma.
Gender:
ALL
Ages:
Between 18 years and 130 years
Trial Updated:
04/25/2025
Locations: Research Site, Phoenix, Arizona +19 locations
Conditions: Hepatocellular Carcinoma
Register for Updates
A Study to Investigate the Efficacy and Safety of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALIANT)
NCT06196879
Recruiting
The purpose of this study is to evaluate the efficacy and safety of verekitug (UPB-101) in participants with severe asthma. The study will evaluate the incidence of asthma exacerbations, other pharmacodynamic (PD) parameters such as lung function and asthma control, and the safety and tolerability of verekitug (UPB-101) compared to placebo.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/25/2025
Locations: AllerVie Clinical Research, Birmingham, Alabama +147 locations
Conditions: Severe Asthma
Register for Updates
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Recurrent/Metastatic Head and Neck Cancer
NCT06385080
Recruiting
The purpose of this study is to determine safety and preliminary efficacy of amivantamab monotherapy, amivantamab in addition to pembrolizumab, amivantamab in addition to paclitaxel and amivantamab in addition to pembrolizumab and carboplatin in participants with recurrent/metastatic head and neck cancer. The study will also confirm the recommended Phase 2 combination dose (RP2CD) for amivantamab in addition to paclitaxel.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: University of California at San Diego Moores Cancer Center, La Jolla, California +51 locations
Conditions: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Register for Updates
A Study to Evaluate Preventive Treatments for Talquetamab-related Oral Toxicity
NCT06500884
Recruiting
The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, and to better characterize the signs or symptoms of talquetamab-related taste changes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Yale University School Of Medicine, New Haven, Connecticut +9 locations
Conditions: Relapse Multiple Myeloma, Refractory Multiple Myeloma
Register for Updates
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT06533059
Recruiting
The purpose of this study is to characterize the safety and tolerability of ALTA2618 in adults with AKT1 E17K-mutant advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Research Site, La Jolla, California +32 locations
Conditions: Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer, Advanced Solid Tumor
Register for Updates
Efficacy, Safety, and Tolerability of Once Daily Oral Administration of AZD5004 Versus Placebo for 26 Weeks in Adults With Type 2 Diabetes Mellitus.
NCT06579105
Recruiting
This is a Phase IIb, randomised, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety and tolerability of AZD5004 in adults with type 2 diabetes mellitus, compared to placebo and active comparator.
Gender:
ALL
Ages:
All
Trial Updated:
04/25/2025
Locations: Research Site, Mobile, Alabama +120 locations
Conditions: Diabetes Mellitus, Type 2
Register for Updates
A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT06624059
Recruiting
The objective of this study is to evaluate the efficacy and/or safety of multiple therapies in patients with early-stage resectable NSCLC. Cohort B1 is a phase II cohort that will evaluate the safety, and efficacy of alectinib in combination with up to four cycles of platinum-based chemotherapy in the adjuvant setting post complete surgical resection. Cohort B2 is a phase II cohort that will evaluate the efficacy and safety of perioperative alectinib in combination with chemotherapy in the neoad... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/25/2025
Locations: Clinical Research Alliance, Westbury, New York +22 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Study to Investigate the Pharmacokinetics, Safety, Tolerability, and Efficacy of AZD0780 With Ezetimibe Combinations in Healthy Adults With Elevated LDL-C.
NCT06742853
Recruiting
The main aim of this study is to assess the effects of AZD0780 when added on top of ezetimibe or ezetimibe and rosuvastatin or ezetimibe and bempedoic acid.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/25/2025
Locations: Research Site, Glendale, California +2 locations
Conditions: Dyslipidemia
Register for Updates